AUTHOR=De Mattia Elena , Cecchin Erika , Montico Marcella , Labriet Adrien , Guillemette Chantal , Dreussi Eva , Roncato Rossana , Bignucolo Alessia , Buonadonna Angela , D’Andrea Mario , Coppola Luigi , Lonardi Sara , Lévesque Eric , Jonker Derek , Couture Félix , Toffoli Giuseppe TITLE=Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients JOURNAL=Frontiers in Pharmacology VOLUME=9 YEAR=2018 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00367 DOI=10.3389/fphar.2018.00367 ISSN=1663-9812 ABSTRACT=
Pharmacogenomics has largely been applied to the personalization of irinotecan-based treatment, focusing mainly on the study of genetic variants in adsorption, distribution, metabolism, and excretion (ADME) genes. The transcriptional control of ADME gene expression is mediated by a set of nuclear factors responding to cancer-related inflammation, which could have pharmacological implications. The aim of the present study was to uncover novel genetic predictors of neutropenia and gastrointestinal toxicity risk among 246 haplotype-tagging polymorphisms in 22 genes encoding inflammation-related cytokines and transcriptional regulators of ADME genes. The study comprised overall more than 400 metastatic colorectal cancer (mCRC) patients treated with first-line FOLFIRI, grouped in a discovery and a replication cohorts. A concordant protective effect of